Optimal reperfusion in NoS Malcolm Metcalfe. Optimum reperfusion Extensive data now available has lead to the formulation of guidelines essentially common.

Slides:



Advertisements
Similar presentations
Slide Gallery Simple Slide Format AvA Aortic Valve Bypass Graft System.
Advertisements

Patient Oriented Therapy for STE-MI
An audit of the antithrombotic therapy for the management of valve repair or replacement Gellatly RM 1,2, Maydelmin D 1, Connell C 1, Marasco S 3, Zimmet.
Degli Studi e dei Registri: sul Territorio
Presenter Disclosure Information
Chapter 9 Growth.
Multiplication X 1 1 x 1 = 1 2 x 1 = 2 3 x 1 = 3 4 x 1 = 4 5 x 1 = 5 6 x 1 = 6 7 x 1 = 7 8 x 1 = 8 9 x 1 = 9 10 x 1 = x 1 = x 1 = 12 X 2 1.
Division ÷ 1 1 ÷ 1 = 1 2 ÷ 1 = 2 3 ÷ 1 = 3 4 ÷ 1 = 4 5 ÷ 1 = 5 6 ÷ 1 = 6 7 ÷ 1 = 7 8 ÷ 1 = 8 9 ÷ 1 = 9 10 ÷ 1 = ÷ 1 = ÷ 1 = 12 ÷ 2 2 ÷ 2 =
1 Copyright © 2008 Cisco Systems, Inc. All rights reserved. Cisco Confidential Internet Business Solutions Group Video : responding to medical needs regardless.
1 Centre for Market and Public Organisation Health Care Reform: Evidence and Issues Carol Propper Public Service Reform Seminar March 2009.
Hip fracture NICE quality standard March 2012 ABOUT THIS PRESENTATION:
Marek Kondys, MD Paweł Buszman, MD, FESC, FACC
Transcatheter aortic valve implantation
Types of AVR Examples of replacement aortic valves: a) shows an aortic homograft, b) and c) show a xenograft, d) shows a ball and cage valve, e) shows.
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
LEARNING SESSION ONE 29 TH OCTOBER 2013 MATERNITY QUALITY IMPROVEMENT.
Transcatheter Aortic Valve Therapies
Scotland National Rural Network Rural Tayside Event 23 April 2010 Update on Rural Priorities Mike Strachan, Policy and Development Officer.
Perioperative Issues Dr John Oyston Dept of Medicine Rounds April 15 th 2008.
Alison Halliday, Professor of Vascular Surgery, University of Oxford 4 th April 2013 Trial update – 1169 Patients so far- Well done, what’s next? 1.
© CM Gibson 2006 Cross-sections of left ventricle after experimental coronary artery occlusion Cross-sections of left ventricle after experimental coronary.
1 Outcomes for Patients with ST-Elevation Myocardial Infarction in Hospitals With and Without Onsite Coronary Artery Bypass Graft Surgery: The New York.
Stroke Care in the UK Tony Rudd. Organisation of Services 120,000 new strokes per year Approx 200 hospitals treating acute stroke patients Most services.
Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.
BASE HOSPITAL GROUP ONTARIO Chapter 3 for 12 Lead Training -WHY 12 LEAD- Ontario Base Hospital Group Education Subcommittee 2008 TIME IS MUSCLE.
Contribution to the panel discussion by OCTAVIO GRANADO, SECRETARY OF STATE FOR SOCIAL SECURITY OF SPAIN CONFERENCE “ASSURING ADEQUATE PENSIONS AND SOCIAL.
Commissioning for Crisis Response Creating a Market Position Statement for homelessness prevention Westgate Community Complex 10 th May 2013.
Chapter 3 for 12 Lead Training -Precourse-
Christina Bannister, Steve Livesey Wessex Cardiothoracic Centre Southampton General Hospital.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for STEMI: The Mayo Clinic Protocol Henry H. Ting, MD, MBA Associate Professor of.
NORTH OF SCOTLAND PLANNING GROUP CARDIAC PLANNING EVENT 24 th February 2010 Aberdeen.
PPCI – National Update NCBC Workshop Jim McLenachan, National Clinical Lead for PPCI, NHS Improvement, England. London, 24 th November, NCBC Annual.
PICO Question In patients over the age of 65 with symptomatic aortic stenosis, will standard aortic valve replacement or transcatheter aortic valve replacement.
Professor Roger Boyle CBE National Director for Heart Disease and Stroke Department of Health PCI in the UK: Fit for service? A view from the Department.
The Integrated Croydon Cardiac Rehabilitation Team Nurses - Sarah Hicks, Mary Stanley, Angela White, Elisabeth Visagie and Carmel Messenger Physiotherapist.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
The Heart of the Matter A Journey through the system of care.
Trans-catheter Aortic Valve Replacement: a UK update. Dr Martyn Thomas Guys and St Thomas’ Hospital.
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
Does Openness Improve Outcome ? The North-West Quality Improvement Program Dr R H Stables Cardiothoracic Centre Liverpool.
Surgical outcome of native valve infective endocarditis in srinagarind hospital
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
A view from the Clinical Lead Malcolm Metcalfe. NoS Cardiology Although much good work has been achieved there remain major challenges ahead. In order.
AA 2008 Session III: STEMI The UK data Mark de Belder The James Cook University Hospital Middlesbrough.
Aortic Stenosis -The Unmet Need Simon Ray University Hospitals of South Manchester ACI 2009.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Dr Martyn Thomas Kings College Hospital Primary angioplasty “A UK Experience” “The UK experience”
ANNA PRICE CHD PROJECT MANAGER BEDFORDSHIRE & HERTFORDSHIRE LOCALITIES EAST OF ENGLAND AMBULANCE SERVICE.
Berkshire Weight Loss Surgery Royal Berkshire Hospital, Reading James Ramus, Consultant UGI & Bariatric Suregon.
Vascular Surgery in Thames Valley Dr Will Orr Clinical Lead CVD Thames Valley NHS England 1.
North of Scotland Planning Group North of Scotland Planning Group North of Scotland Cardiac Services …so what are the challenges? Mr Hussein El-Shafei.
EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.
Use of Postmarket Data to Support Premarket Approvals
Anita W. Asgar MD, FRCPC, FACC Montreal Heart Institute
TAVR-Endocarditis Tarek Chami, MD
The Spanish Data Bank PEGASO M. Martínez-Sellés
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Heart Disease in the Acute Hospital
Michael Mack, M.D. Dallas, TX February 21, 2010
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
Balloon-Expandable Transcatheter Valve System : OUS Data
Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.
STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES
Making Health Care Decisions End of Life Care
Reply The Annals of Thoracic Surgery
Optimal reperfusion in NoS Malcolm Metcalfe. Optimum reperfusion Extensive data now available has lead to the formulation of guidelines essentially common.
Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.
Presentation transcript:

Optimal reperfusion in NoS Malcolm Metcalfe

Optimum reperfusion Extensive data now available has lead to the formulation of guidelines essentially common to UK, Europe, North American and Antipodes. The crux of this are the major benefits which result from mechanical revascularisation (PPCI) as opposed to thrombolytic therapy. This advantage however is maximal within 90 minutes from diagnosis (ECG) to balloon inflation and probably non-existent greater than 120 minutes.

Lothian pilot Invaluable source of real world data Major logistic issue is transport Major logistic issue is transport Fixed front-end (15mins) and lab (35mins) times leaving maximum ambulance drive time of 40 mins Fixed front-end (15mins) and lab (35mins) times leaving maximum ambulance drive time of 40 mins Decision support system is essential Decision support system is essential Feedback to ambulance service important Feedback to ambulance service important Approximately 50% of AMIs occur in office hours Approximately 50% of AMIs occur in office hours

Isochrones

Other important considerations As many patients are outwith of a 40 minute drive time pre-hospital thrombolysis (PHT) is next best option 30% of these patients will not reperfuse and will require rescue PCI (Drip and ship). Inverness will only be office hours PCI centre from August Double jump admissions and A&E Departments are to be discouraged as they slow down this assessment and time to rescue with attendant increased mortality/morbidity.

Proposed rules of engagement Islands Drip and Ship with immediate air transport to Aberdeen. Drip and Ship with immediate air transport to Aberdeen.Highland After August patients within 40 min drivetime (inc W Moray) and within office hours to be taken to Raigmore for PPCI After August patients within 40 min drivetime (inc W Moray) and within office hours to be taken to Raigmore for PPCI Other patients to be given PHT and those which require rescue to be done locally (office hours) or immediate air transport to Aberdeen. Other patients to be given PHT and those which require rescue to be done locally (office hours) or immediate air transport to Aberdeen. This to be coordinated by local decision support service This to be coordinated by local decision support service Wick, Fort William and Skye probably hybrid of above coordinated by decision support service Wick, Fort William and Skye probably hybrid of above coordinated by decision support service

Proposed rules of engagement Grampian Office hours PPCI currently available with 24/7 emergency service available. Office hours PPCI currently available with 24/7 emergency service available. Plans to extent this to 24/7 later this year. Plans to extent this to 24/7 later this year. Other Grampian patients to be given PHT and shipped to Aberdeen. Other Grampian patients to be given PHT and shipped to Aberdeen. STEMI patients should bypass Dr Grays and all other community hospitals STEMI patients should bypass Dr Grays and all other community hospitals

Proposed rules of engagement Tayside Office hours PPCI service currently available Office hours PPCI service currently available BC acceptance to extend service to 24/7 from April BC acceptance to extend service to 24/7 from April May include N Fife too May include N Fife too Unusual population as majority live within 40 mins of Ninewells. Unusual population as majority live within 40 mins of Ninewells. Decision support will still direct to PHT with transfer to Ninewells as appropriate. Decision support will still direct to PHT with transfer to Ninewells as appropriate.

Discussion… So how do we make this all work?

Transcatheter aortic valve implantation (TAVI) Malcolm Metcalfe

TAVI Potentially life-saving therapy for patients unsuitable for conventional aortic valve replacement. No longer regarded as experimental At the end of 2009 c 8000 valves were implanted world- wide. 2 major competitors Medtronic Core-Valve Medtronic Core-Valve Edwards Sapien Edwards Sapien 3 methods of implantation Trans-arterially Trans-arterially Trans-apically Trans-apically Subclavian approach Subclavian approach

Surgical intervention should be performed promptly once even … minor symptoms occur 1 Surgical intervention should be performed promptly once even … minor symptoms occur 1 Chart: Ross J Jr, Braunwald E. Aortic stenosis. Circulation 1968;38 (Suppl 1) 1 C.M. Otto. Valve Disease: Timing of Aortic Valve Surgery. Heart 2000 Chart:: Ross J Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38 (Suppl 1): Valvular Aortic Stenosis in Adults (Average Course)

Mortality in Aortic Valve Replacement Burr et al, Annals Thor Surg, 1995;60:S n = 1.984

Calculated numbers Probably 1000 for UK as a whole c100 for Scotland = 16 per million of population

What is the risk? Initial mortality approximately 10% Improving Core valve May 2008: 30 day mortality = 8% in first 1000 European implants Core valve May 2008: 30 day mortality = 8% in first 1000 European implants Edwards May 2009: 30 day mortality = 6.3% for TAVI and 10.3% for trans-apical in 1038 patients. Edwards May 2009: 30 day mortality = 6.3% for TAVI and 10.3% for trans-apical in 1038 patients.

Risks and benefits 3 year experience (Vancouver data to be published in Circulation) 168 patients, mean age patients, mean age 84. TAVI = 113 TAVI = 113 Trans-apical = 55 Trans-apical = 55 Major complications Transfusion 11.5% Transfusion 11.5% Major vascular surgery 6.6% Major vascular surgery 6.6% Pacemaker 5.4% Pacemaker 5.4% Renal failure 6% Renal failure 6% Pneumonia 4.8% Pneumonia 4.8% 30 days 14.9% 30 days 14.9%

Risks and benefits – Vancouver experience Mortalityp value Transarterially overall8.0% st half12.3% 2 nd half3.6% Transapically overall18.2% st half25% 2 nd half11.1%

Risks and benefits – Vancouver experience Benefits were sustained All NYHA class 3 & 4 patients improved by 1 class. All NYHA class 3 & 4 patients improved by 1 class. At 1 year 75% still alive (99) of which 77 were in class 1 or 2. At 1 year 75% still alive (99) of which 77 were in class 1 or 2.

Centres All 3 Scottish cardiothoracic centres could be capable of undertaking these procedures. Stringent criteria laid down as per formal commissioning framework (DH 3/09) Centres must undertake implants in first year and maintain this. At 16 per million population = pa for Scotland Initial rate may be less Expensive, 50% more than conventional AVR Thus need to decide how to deliver service

Genie is now out of the bottle – how to progress service All UK Cardiologists and Cardio-Thoracic surgeons are united in their support for this technology. Scotland lags far behind England, Wales, Other European countries and North America. Many referrals have already been made to English centres with good short-term results It would be regarded as morally indefensible by clinicians to try and stop this service Clinicians who do not offer this option could be subject to legal action. Its relatively expensive but compare, for example, to new cancer drugs It is no longer experimental but longer-term results are not well described and waters are being muddied by proposals to swop conventional high risk patients to TAVI (unproven, not costed and not licensed).